From Biomarkers to Prevention: A White Paper on Quantifying Brain Clearance Through BAT Testing and BATChecks

This white paper introduces a proposed real-world framework for non-invasive brain clearance monitoring, extending plasma-based biomarker testing beyond traditional cerebrospinal fluid (CSF) diagnostics. The BAT Testing and BATCheck system is designed for preventive neuroscience applications, integrating validated biomarkers of Beta-Amyloid (Aβ) and Tau (T) with contextual metabolic and inflammatory indicators. The observations described are based on early, de-identified registry data and are not yet peer-reviewed. This model aims to demonstrate the feasibility of large-scale clearance monitoring, not to claim clinical efficacy. The BAT Testing and BATCheck framework extends this evolution into real-world preventive neuroscience, integrating validated assays for Beta-Amyloid (Aβ) and Tau (T) proteins with contextual metabolic, inflammatory, and hormonal markers. This paper outlines how BAT Testing measures molecular clearance efficiency while BATCheck identifies upstream systemic influences that modulate that efficiency. Together, they operationalize Clearance Monitoring, a measurable biological rhythm rather than a diagnostic endpoint. Positioned alongside World Health Organization (WHO), National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC) priorities for dementia prevention, this framework demonstrates that clearance dynamics can be tracked, stabilized, and analyzed across populations without reliance on invasive procedures. The framework builds upon a peer-reviewed foundation of validated plasma biomarker research, translating those findings into a scalable, real-world preventive model.